Skip to main content
Signal8
Launch Terminal

Savara Inc (SVRA)

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Savara Inc. logo

Savara Inc.

NASDAQ:SVRAHealthcare
-2.63%$4.82
AH$4.87+1.04%vs close
Mkt Cap$990.32M
Float143.33M
O/S205.46M
Vol
$ Vol
RVOL
Inst Own-
SI20.1%
Earnings
Dilution
Savara Inc. logoNASDAQ:SVRA$4.82-2.63%
Upcoming Catalysts
  • MOLBREEVIPDUFA
    autoimmune pulmonary alveolar proteinosis
    Cash runway at this date: 13mo
    Nov 22, 2026in 20 daysPR
Phase Distribution
25 lead-sponsored trials·2 active·16 completed
Phase 17
Phase 29
Phase 38
Not applicable1
(2 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease

    poloxamer 188

    Sickle Cell Anemia

    Enrollment
    300
    Start
    Nov 1997
    Primary Completion
    -
    Completion
    Nov 1999
    NCT00004408
  • Phase 3
    Unknown status

    Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.

    5- Fluorouracil (5-FU), bevacizumab (Avastin)

    Metastatic Colorectal Cancer, Colon Cancer +1

    Enrollment
    1,200
    Start
    May 2006
    Primary Completion
    -
    Completion
    -
    NCT00337389
  • Phase 3
    Completed

    Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)

    Saline, MST-188

    Vaso-occlusive Crisis, Sickle Cell Disease

    Enrollment
    388
    Start
    May 2013
    Primary Completion
    Feb 2016
    Completion
    -
    NCT01737814
  • Phase 3
    Completed

    Evaluation of Repeat Administration of Purified Poloxamer 188

    MST-188

    Sickle Cell Disease

    Enrollment
    16
    Start
    Jun 2015
    Primary Completion
    Sep 2016
    Completion
    -
    NCT02449616
  • Phase 3
    Completed

    AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

    Vancomycin inhalation powder, Placebo inhalation powder

    MRSA, Cystic Fibrosis

    Enrollment
    188
    Start
    Sep 2017
    Primary Completion
    Jul 2020
    Completion
    Jan 2021
    NCT03181932
  • Phase 3
    Terminated

    Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis

    Molgramostim

    Autoimmune Pulmonary Alveolar Proteinosis

    Enrollment
    60
    Start
    Apr 2018
    Primary Completion
    Jan 2021
    Completion
    Jan 2021
    NCT03482752
  • Phase 3
    Active, not recruiting

    Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Molgramostim, Placebo

    Autoimmune Pulmonary Alveolar Proteinosis

    Enrollment
    164
    Start
    May 2021
    Primary Completion
    Nov 2023
    Completion
    May 2027est.
    NCT04544293
  • Phase 3
    Recruiting

    Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

    Molgramostim

    Autoimmune Pulmonary Alveolar Proteinosis

    Enrollment
    5
    Start
    Oct 2025
    Primary Completion
    Jun 2027est.
    Completion
    Dec 2027est.
    NCT06431776
  • Phase 2
    Completed

    Clinical Trial in Patients With Metastatic Colorectal Cancer

    CoFactor and 5FU

    Colon Cancer, Rectal Cancer

    Enrollment
    48
    Start
    Apr 2004
    Primary Completion
    -
    Completion
    Jan 2007
    NCT00081627
  • Phase 2
    Completed

    Clinical Trial in Patients With Metastatic Colorectal Cancer

    CoFactor, 5-FU

    Colon Cancer, Rectal Cancer

    Enrollment
    300
    Start
    May 2005
    Primary Completion
    Mar 2008
    Completion
    -
    NCT00235898
  • Phase 2
    Unknown status

    5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Treating Advanced Breast Cancer Patients

    CoFactor (ANX-510)

    Breast Cancer

    Enrollment
    31
    Start
    Feb 2006
    Primary Completion
    -
    Completion
    -
    NCT00434369
  • Phase 2
    Completed

    Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

    Vancomycin hydrochloride inhalation powder, Placebo inhalation powder

    Cystic Fibrosis

    Enrollment
    87
    Start
    Mar 2013
    Primary Completion
    Nov 2014
    Completion
    Nov 2014
    NCT01746095
  • Phase 2
    Terminated

    Evaluation of MST-188 in Acute Lower Limb Ischemia

    MST-188, Saline

    Acute Limb Ischemia

    Enrollment
    4
    Start
    Jun 2014
    Primary Completion
    Dec 2016est.
    Completion
    -
    NCT02093468
  • Phase 2
    Terminated

    Evaluation of Vepoloxamer in Chronic Heart Failure

    Vepoloxamer

    Chronic Heart Failure

    Enrollment
    10
    Start
    Oct 2015
    Primary Completion
    Oct 2016
    Completion
    -
    NCT02596477
  • Phase 2
    Completed

    Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis

    Molgramostim, Placebo

    Autoimmune Pulmonary Alveolar Proteinosis

    Enrollment
    139
    Start
    Mar 2016
    Primary Completion
    Apr 2019
    Completion
    Sep 2019
    NCT02702180
  • Phase 2
    Completed

    Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection

    Inhaled molgramostim, Antimycobacterial regimen

    Mycobacterium Infections, Nontuberculous

    Enrollment
    32
    Start
    Mar 2018
    Primary Completion
    Oct 2019
    Completion
    Jan 2020
    NCT03421743
  • Phase 2
    Terminated

    Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

    Molgramostim nebulizer solution

    Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)

    Enrollment
    14
    Start
    Jun 2019
    Primary Completion
    Oct 2020
    Completion
    Oct 2020
    NCT03597347
  • Phase 1
    Completed

    A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.

    Vinorelbine Tartrate

    Breast Cancer, Non-small Cell Lung Cancer +1

    Enrollment
    31
    Start
    Feb 2007
    Primary Completion
    Nov 2007
    Completion
    Dec 2007
    NCT00432562
  • Phase 1
    Completed

    A Clinical Trial of CoFactor Formulations and Leucovorin Administered Intravenously in Healthy, Adult Subjects.

    CoFactor, Leucovorin

    Healthy Adults

    Enrollment
    15
    Start
    Apr 2008
    Primary Completion
    May 2008
    Completion
    May 2008
    NCT00663481
  • Phase 1
    Completed

    A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer

    ANX-514, docetaxel

    Advanced Cancer

    Enrollment
    39
    Start
    Apr 2008
    Primary Completion
    Apr 2009
    Completion
    Apr 2009
    NCT00664170
  • Phase 1
    Completed

    Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics

    AeroVanc, IV vancomycin hydrochloride

    Healthy, Cystic Fibrosis

    Enrollment
    25
    Start
    Nov 2011
    Primary Completion
    Mar 2012
    Completion
    Mar 2012
    NCT01537666
  • Phase 1
    Completed

    ANX-188 Thorough QT/QTc Study in Healthy Volunteers

    ANX-188 Therapeutic Dose, ANX-188 Supratherapeutic dose

    Healthy

    Enrollment
    72
    Start
    Feb 2013
    Primary Completion
    Apr 2013
    Completion
    Jun 2013
    NCT01790087
  • Phase 1
    Completed

    Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects

    Molgramostim, Placebo

    Pulmonary Alveolar Proteinosis, Bronchiectasis +2

    Enrollment
    42
    Start
    May 2015
    Primary Completion
    Oct 2015
    Completion
    Oct 2015
    NCT02468908
  • Phase 1
    Completed

    Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer

    Vepoloxamer

    Pharmacokinetics of Vepoloxamer, Healthy Volunteers +1

    Enrollment
    27
    Start
    Jan 2016
    Primary Completion
    Nov 2016
    Completion
    -
    NCT02646358
  • Expanded access
    Available

    Molgramostim Nebulizer Solution Expanded Access Program Protocol

    Molgramostim nebulizer solution

    Autoimmune Pulmonary Alveolar Proteinosis

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT06546098
Search ClinicalTrials.gov for “Savara”